Leap Therapeutics (NASDAQ:LPTX) had its price target lowered by HC Wainwright from $5.00 to $4.00 in a research note released on Monday morning, BenzingaRatingsTable reports. The brokerage currently has a buy rating on the stock.
Several other research analysts have also recently issued reports on LPTX. LADENBURG THALM/SH SH reissued a buy rating and issued a $8.00 price target on shares of Leap Therapeutics in a research note on Sunday, July 19th. ValuEngine raised Leap Therapeutics from a hold rating to a buy rating in a research note on Friday, May 1st. Raymond James set a $2.50 target price on Leap Therapeutics and gave the company an outperform rating in a research note on Friday, June 12th. Finally, Piper Sandler assumed coverage on Leap Therapeutics in a research note on Monday, June 29th. They set an overweight rating and a $6.00 target price for the company. Seven investment analysts have rated the stock with a buy rating, Leap Therapeutics has a consensus rating of Buy and a consensus price target of $4.79.
NASDAQ:LPTX opened at $1.85 on Monday. Leap Therapeutics has a 1 year low of $0.57 and a 1 year high of $3.18. The stock has a market cap of $115.14 million, a price-to-earnings ratio of -1.41 and a beta of 1.89. The business has a fifty day moving average of $2.01 and a 200-day moving average of $2.07. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.82 and a current ratio of 9.55.
Leap Therapeutics (NASDAQ:LPTX) last released its quarterly earnings results on Thursday, August 13th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.18) by $0.06. On average, equities research analysts predict that Leap Therapeutics will post -0.77 EPS for the current year.
In other news, major shareholder Perceptive Advisors Llc bought 1,750,000 shares of the firm’s stock in a transaction that occurred on Monday, June 22nd. The stock was acquired at an average price of $2.00 per share, with a total value of $3,500,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 25.89% of the company’s stock.
Several large investors have recently added to or reduced their stakes in the stock. FMR LLC raised its holdings in Leap Therapeutics by 63.3% during the first quarter. FMR LLC now owns 1,563,124 shares of the company’s stock worth $2,923,000 after acquiring an additional 606,000 shares in the last quarter. Personal CFO Solutions LLC acquired a new stake in shares of Leap Therapeutics in the 1st quarter valued at $101,000. Gratus Capital LLC acquired a new stake in shares of Leap Therapeutics in the 1st quarter valued at $40,000. BlackRock Inc. boosted its holdings in shares of Leap Therapeutics by 21.5% in the 1st quarter. BlackRock Inc. now owns 38,946 shares of the company’s stock valued at $62,000 after purchasing an additional 6,897 shares in the last quarter. Finally, Sphera Funds Management LTD. acquired a new stake in shares of Leap Therapeutics in the 1st quarter valued at $948,000. Institutional investors and hedge funds own 31.38% of the company’s stock.
Leap Therapeutics Company Profile
Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in Phase I/II clinical trial in patients with esophagogastric, biliary tract, gynecologic, and non-small cell lung cancers, as well as hepatocellular carcinoma, a type of liver cancer.
Featured Story: What is a capital gain?
Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.